Tango's Vopimetostat/Daraxonrasib Combo Delivers 82% ORR in 2L/3L Pancreatic Cancer

What happened

Tango Therapeutics announced Phase 1/2 data showing an 82% objective response rate, median progression-free survival not yet reached, and a 9-month PFS rate of 88% in patients with second- or third-line pancreatic cancer treated with vopimetostat plus daraxonrasib. This combination result starkly improves on vopimetostat's prior monotherapy data, which had a 25% ORR and 7.2-month median PFS in the same setting, suggesting the addition of the RAS inhibitor unlocks a substantially more active regimen. The news lands after the stock's 350% rise over the past year, with the company trading around $12.51 and facing a pivotal trial for vopimetostat monotherapy expected to start in 2026. While the headline numbers are compelling, they come from an early-phase trial with no disclosed patient count, no randomization, and a company-issued press release that lacks granularity on durability, safety, and biomarker selection. Investors must weigh this promising signal against Tango's still pre-revenue status, ~$365 million cash runway into 2028, and the risk that a single-arm pivotal may face regulatory headwinds.

Implication

The combination data, if validated in larger cohorts, would meaningfully expand vopimetostat's addressable market and de-risk its path to approval by offering a differentiated, higher-efficacy option in pancreatic cancer. However, the absence of key trial details—such as sample size, duration of response, and complete response rates—means the 82% ORR could be an artifact of a small, favorable population and may not hold up in a registrational setting. Tango still faces the formidable challenge of competing against Amgen's AMG 193, which has large-company resources and is already in randomized trials, and any regulatory insistence on a controlled pivotal could strain the company's balance sheet. While the stock may rally on this news, the current valuation already incorporates substantial success for the PRMT5 franchise, leaving limited margin of safety if the combo data disappoints over time. Existing holders should consider holding with a tight risk limit, while prospective investors should wait for confirmation from a larger dataset or a price decline closer to the recent financing level of $8.66.

Thesis delta

The previous thesis leaned toward trimming or selling because monotherapy data were only modestly better than historical controls and cash burn was high. The new combination data shifts the balance toward a more neutral or slightly positive stance, as 82% ORR suggests vopimetostat may be best-in-class when paired with a RAS inhibitor. However, the shift is limited by the preliminary nature of the data and the lack of confirmatory evidence, so the core risk of single-program dependence and competitive pressure remains.